Welcome to a new episode of AI Chats, a podcast series produced by the law firm of Haynes and Boone, and lawyers from its AI and Deep Learning Practice Group to explore the exciting, ever-evolving, and occasionally controversial world of artificial intelligence.Today for our latest episode we are going to talk about Why Pharma Should Invest in Patenting AI. Moderator: <a href='https://www.haynesboone.com/people/goryunov-eugene'>Eugene Goryunov</a>, Partner, Haynes and Boone Featured Speakers: <ul><li><a href='https://www.haynesboone.com/people/shier-vincent'>Vincent Shier</a>, Partner, Haynes and Boone</li><li><a href='https://www.haynesboone.com/people/blikshteyn-dina'>Dina Blikshteyn</a>, Counsel, Haynes and Boone</li><li><a href='https://www.haynesboone.com/people/cohen-brooke'>Brooke Cohen</a>, Associate, Haynes and Boone</li></ul>AI Chats a podcast produced by Haynes Boone. © 2024 Haynes and Boone, LLP All rights reserved.

AI Chats Episode 24: Patent Eligibility Issues In Pharma

Welcome to AI Chats, a podcast series by Haynes and Boone, LLP covering a broad range of technology and legal topics in artificial intelligence (“AI”) and deep learning. Renowned AI theorists and developers join Haynes and Boone lawyers to discuss the current and prospective uses of AI in a broad range of technology areas, including machine learning, healthcare, autonomous driving, cloud computing, natural language processing, and medical devices. We discuss novel legal issues presented by using AI in business operations, intellectual property portfolio development, privacy and data protection, and employment law, among other topics.